Suzhou Sepax Technologies
688758
Juneway Electronic Technology
301458
Jiujiang Defu Technology
301511
Cubic Digital Technology
300344
Ningbo Shuanglin Auto Parts
300100
CN Stock MarketDetailed Quotes
603676 Xizang Weixinkang Pharmaceutical
- 9.41
- -0.31-3.19%
Market Closed Jan 10 15:00 CST
4.09BMarket Cap16.57P/E (TTM)
9.73High9.41Low19.44KlotVolume9.70Open9.72Pre Close18.53MTurnover0.45%Turnover Ratio19.13P/E (Static)435.16MShares11.3052wk High2.90P/B4.09BFloat Cap5.8552wk Low10.69Limit Up435.16MShs Float26.46Historical High8.75Limit Down3.29%Amplitude5.68Historical Low0.45Dividend TTM9.54Avg Price11.06KlotAsk4.75%Div YieldTTM100Lot Size7.87KlotBid
Xizang Weixinkang Pharmaceutical News
Express News | Tibet Weixinkang Pharmaceutical: Subsidiary Yangpu Jingtai Calcium Gluconate Injection has passed the consistency evaluation for generic drugs.
Express News | Tibet Weixinkang Pharmaceutical: Children's multivitamin injection is renewed and included in the national medical insurance catalog.
Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary pharmaceuticals renewed in the national medical insurance catalog.
On November 29, Gelonghui reported that tibet weixinkang pharmaceutical (603676.SH) announced, according to the notice from the National Medical Insurance Administration and the Ministry of Human Resources and Social Security regarding the issuance of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Directory (2024)" (referred to as "National Medical Insurance Directory (2024)"), that the fully-owned subsidiary of tibet weixinkang pharmaceutical, inner mongolia baiyi pharmaceutical co., ltd., pediatric multi-vitamins injection (13) has been renewed and included in the "National Medical Insurance Directory (2024)" during the agreement period.
Tibet Weixinkang Pharmaceutical (603676) deep research report: domestic leader in parenteral nutrition, operational development welcomes a new cycle.
Tibet Weixinkang Pharmaceutical is a leading company in domestic parenteral nutrition medications. Tibet Weixinkang was established in 2006 and has been deeply engaged in the parenteral nutrition sector, possessing significant advantages in areas such as compound vitamins, intravenous trace elements, and intravenous electrolytes. The core product is an injectable multivitamin.
tibet weixinkang pharmaceutical (603676.SH): First-time repurchase of 0.1567 million shares of the company's stock
Gelonghui announced on November 25 that Tibet Weixinkang Pharmaceutical (603676.SH) has repurchased 156,700 shares of the company through centralized bidding for the first time on November 25, 2024, representing 0.0360% of the company's total share capital. The highest fill price was 9.9 yuan per share, the lowest fill price was 9.72 yuan per share, and the total transaction amount was 1,541,919 yuan (excluding commission and other trading fees).
Express News | Tibet Weixinkang Pharmaceutical: Subsidiary withdraws the registration application for compound amino acids (16) dipeptide (1) injection.
tibet weixinkang pharmaceutical (603676.SH): Compound Electrolyte Injection (II) Passes Generic Drug Consistency Evaluation
Tibet Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (简...
tibet weixinkang pharmaceutical (603676.SH) equity distribution in the first three quarters of 2024: 0.162 yuan per share, with equity registration on November 11th.
tibet weixinkang pharmaceutical (603676.SH) issued a notice on equity distribution for the first three quarters of 2024, and the profit distribution for this time is based on the plan...
Express News | tibet weixinkang pharmaceutical: Subsidiary pharmaceutical products have passed the evaluation of generic drug quality and efficacy consistency.
Tibet Weixinkang Pharmaceutical (603676) company brief report: The impact of centralized procurement is gradually being digested, and the performance is ushering in a turning point.
Event: The company released its Q3 report for 2024, achieving revenue of 0.994 billion yuan (-6.30%) in the first three quarters, with a net income attributable to shareholders of the listed company of 0.243 billion yuan (+15.71%), attributable to
tibet weixinkang pharmaceutical (603676.SH): Not yet repurchased
On November 4, tibet weixinkang pharmaceutical (603676.SH) announced that, as of October 31, 2024, the company has repurchased 0 shares.
Wei Xinkang: Report for the Third Quarter of 2024 of Tibet Weixinkang Pharmaceutical Co., Ltd.
Report for the third quarter of 2024 of Tibet Weixinkang Pharmaceutical Co., Ltd.
tibet weixinkang pharmaceutical (603676.SH): The net income for the first three quarters was 0.243 billion yuan, a year-on-year increase of 15.71%.
GeLongHui on October 28thཨTibet Weixinkang Pharmaceutical (603676.SH) released its third quarter report, with revenue of 0.994 billion yuan in the first three quarters, a 6.30% year-on-year decrease, a net income of 0.243 billion yuan, a 15.71% year-on-year increase, a non-GAAP net profit of 0.197 billion yuan, a 15.84% year-on-year increase, and basic earnings per share of 0.56 yuan.
Tibet Weixinkang Pharmaceutical (603676.SH) released its performance for the first three quarters, with a net income of 0.243 billion yuan, a year-on-year increase of 15.71%.
tibet weixinkang pharmaceutical (603676.SH) released the report for the first three quarters of 2024, during the reporting period the company achieved revenue of 9...
Tibet Weixinkang Pharmaceutical (603676.SH) subsidiary compound electrolyte injection (V) passed the generic drug consistency evaluation
Tibet Weixinkang Pharmaceutical (603676.SH) announced that recently, its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd...
Tibet Weixinkang Pharmaceutical (603676.SH): Obtained exclusive license for a non-opioid intravenous analgesic drug from AFT Pharmaceuticals.
tibet weixinkang pharmaceutical (603676.SH) announced that its wholly-owned subsidiary, tibet Zhongwei Chengkang Pharmaceutical Co., Ltd. (“Zhongwei Cheng...
Tibet Weixinkang Pharmaceutical (603676.SH): Subsidiary receives drug clinical trial approval notice.
On September 6th, Gelunhui announced that its wholly-owned subsidiary, Beijing Weixinkang Pharmaceutical Research and Development Co., Ltd. (referred to as "Tibet Weixinkang"), has received the approved and issued Drug Clinical Trial Approval Notice for Deoxycholic Acid Injection from the National Medical Products Administration. The deoxycholic acid injection declared by Tibet Weixinkang, a wholly-owned subsidiary of the company, is developed based on Belkyra, a reference preparation marketed by Allergan Pharmaceuticals International/AbbVie S.r.l. Its indication is for improving adults
Express News | Tibet Weixinkang Pharmaceutical: Subsidiary approved for clinical trial of deoxycholic acid injection.
Tibet Weixinkang Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
